Trial
NCT03836053
Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Relapsed and/or Refractory Multiple Myeloma
Intervention
AMG 420
Why stopped
Amgen re-evaluated the portfolio and decided to discontinue clinical development activities for AMG 420.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-11